Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MRG007 · 1 trial · 4 indications
Adverse events that are fatal, life-threatening, or result in hospitalization or prolonged hospitalization, persistent or significant disability/incapacity/substantial disruption of the ability to lead a normal life, congenital anomaly/birth defect or major medical events or reactions
AEs that occur or worsen on or after the first dose of study treatment
Any reaction, side effect, or untoward event that occurs during the course of the clinical trial is considered related to the study drug.
ORR is defined as the proportions of patients with a complete response (CR) and partial response (PR). ORR will be assessed according to RECIST v1.1.
| Arm | Type | Description |
|---|---|---|
| MRG007 | EXPERIMENTAL | - |
| MRG007 and Bevacizumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MRG007 | DRUG | MRG007 will be administrated as specified in the protocol. |
| MRG007 and Bevacizumab | DRUG | MRG007 will be administered as specified in the protocol |
1. Willing to sign the informed consent form and follow the requirements specified in the protocol. 2. Life expectancy ≥ 3 months. 3. Tumor specimen available for CDH17 testing, or agree to biopsy at baseline. 4. Patients with histologically and cytologically confirmed advanced or metastatic solid t...
MRG007 is an investigational small molecule being developed for the treatment of locally advanced or metastatic solid tumors, including colorectal cancer, gastric cancer, and pancreatic cancer. It is currently in Phase 1 clinical development and is not yet approved by the FDA.
MRG007 targets CDH17, a protein involved in cell adhesion. By binding to CDH17, the drug aims to interfere with tumor growth and progression in solid tumors. This mechanism is being evaluated in early-stage clinical trials for patients with advanced cancers.
MRG007 is being developed by ArriVent BioPharma, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AVBP. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in patients with advanced solid tumors.
MRG007 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting patients to assess the drug's safety, tolerability, and preliminary efficacy in advanced solid tumors.
MRG007 is being studied in a Phase 1 clinical trial with the identifier NCT07066657, titled 'A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors.' This recruiting trial plans to enroll approximately 572 participants across the United States and China, including patients with colorectal, gastric, and pancreatic cancers.
Yes, MRG007 is also known as ARR-217. The clinical trial NCT07066657 refers to the drug as MRG007 (ARR-217), indicating that both names are used interchangeably for the same investigational compound being developed by ArriVent BioPharma.